(0.05%) 5 472.21 points
(0.09%) 39 148 points
(0.36%) 17 781 points
(-0.11%) $80.74
(-3.66%) $2.66
(-0.75%) $2 313.40
(0.25%) $28.94
(3.59%) $1 021.80
(0.28%) $0.936
(0.67%) $10.67
(0.46%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide...
Stats | |
---|---|
今日成交量 | 8.20M |
平均成交量 | 996 380 |
市值 | 0.00 |
EPS | $-0.490 ( Q1 | 2021-05-05 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-2.39 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.159 (4.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-08-05 | Stonepine Capital, L.p. | Sell | 6 770 000 | Common Stock |
2021-08-05 | Ludlam William | Sell | 11 799 | Common Stock |
2021-08-05 | Ludlam William | Sell | 45 916 | Stock Option (Right to Buy) |
2021-08-05 | Ludlam William | Sell | 14 531 | Stock Option (Right to Buy) |
2021-08-05 | Ludlam William | Sell | 74 997 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
0.00 |
Last 99 transactions |
Buy: 1 667 356 | Sell: 11 115 504 |
音量 相关性
Chiasma, Inc. 相关性 - 货币/商品
Chiasma, Inc. 财务报表
Annual | 2020 |
营收: | $1.11M |
毛利润: | $1.05M (94.48 %) |
EPS: | $-1.430 |
FY | 2020 |
营收: | $1.11M |
毛利润: | $1.05M (94.48 %) |
EPS: | $-1.430 |
FY | 2019 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.060 |
FY | 2018 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.280 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Chiasma, Inc.
Chiasma, Inc., a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Needham, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。